The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).
None
Any disease/condition that, in the investigator's judgment, may pose an unacceptable safety risk for study participation.
Any AE that resulted in permanent discontinuation of IMP in IM027068 or IM0271015.
Exhibit symptoms of heart failure at rest.
History of lung reduction surgery or lung transplant.